Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

医学 银屑病 危险系数 癌症 内科学 入射(几何) 癌症登记处 置信区间 队列研究 皮肤癌 队列 比例危险模型 肿瘤科 倾向得分匹配 回顾性队列研究 总体生存率 癌症发病率 斑块性银屑病 插补(统计学) 流行病学 皮肤病科 乳腺癌 标准化死亡率 低风险 生存分析 相对风险
作者
Oras Alabas,K.J. Mason,Mark Lunt,Sarah Ryan,Nick J. Reynolds,Catherine H. Smith,Clareann H. Bunker,Christopher E.M. Griffiths,Adèle C. Green,Richard Bruce Warren
出处
标识
DOI:10.1111/jdv.70828
摘要

BACKGROUND: There are concerns that biologic therapies for psoriasis may increase cancer risk. OBJECTIVES: To compare risks of (i) incident cancer excluding keratinocyte carcinomas (KC; hereafter referred to as cancer) and (ii) KC among patients with moderate-to-severe psoriasis treated with biologic versus non-biologic systemic therapies, and across biologic classes. METHODS: Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a UK and Republic of Ireland register collected 2007-2025, were linked to NHS Digital for enhanced cancer ascertainment. Biologic-naïve patients aged ≥16 years with chronic plaque psoriasis and no prior cancer or KC were included. Cancer or KC events occurring within 12 months of treatment initiation were excluded. Crude incidence rates per 1000 person-years (py) with 95% confidence intervals (CI) were calculated. Adjusted hazard ratios (aHRs; 95% CI) were estimated using propensity score-weighted flexible parametric survival models with multiple imputation for missing data. RESULTS: The cancer and KC analyses included 18,894 and 19,144 patients, respectively (58% receiving biologics in both), reflecting differences in outcome-specific exclusion criteria. In 1-year lagged analyses, cancer incidence rates per 1000 person-years were 6.40 [95% CI 5.83-7.02] in biologic initiators and 6.83 [95% CI 6.01-7.76] in non-biologic systemic initiators, with an aHR of 0.91 [95% CI 0.77-1.07]. Corresponding KC incidence rates were 2.63 [95% CI 2.28-3.04] and 2.42 [95% CI 1.96-3.00], respectively, with an aHR of 1.05 [95% CI 0.81-1.35]. Follow-up was shorter for IL-12/23i and IL-17i than for TNFi. Cancer risk did not differ significantly for IL-12/23i or IL-17i versus TNFi, nor was KC risk elevated for IL-12/23i. CONCLUSIONS: This real-world study found no evidence of an increased risk of cancer or KC with biologic compared with non-biologic systemic therapies, or across the biologic classes. Larger studies with longer follow-up, particularly for newer biologics, are needed to clarify long-term risk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
YujieJin发布了新的文献求助10
刚刚
obtu发布了新的文献求助10
刚刚
1秒前
jinin发布了新的文献求助10
1秒前
謓言完成签到,获得积分10
2秒前
落寞灵寒wc完成签到,获得积分10
2秒前
3秒前
3秒前
Patti发布了新的文献求助10
3秒前
Xu完成签到,获得积分10
4秒前
4秒前
Zlion完成签到 ,获得积分10
5秒前
星辰发布了新的文献求助10
5秒前
6秒前
我是老大的应助被清蒸大肥鱼采纳,获得10
6秒前
雄图发布了新的文献求助10
6秒前
7秒前
和谐沛芹发布了新的文献求助10
7秒前
盐水鸭完成签到,获得积分10
7秒前
Hustic完成签到 ,获得积分10
8秒前
8秒前
8秒前
9秒前
邱邵芸发布了新的文献求助10
9秒前
dsy完成签到,获得积分10
9秒前
为Zn发电完成签到,获得积分10
9秒前
AireenBeryl531举报杨凤艳的求助涉嫌违规
10秒前
10秒前
10秒前
吃不饱发布了新的文献求助10
10秒前
10秒前
li完成签到,获得积分10
10秒前
落寞灵寒wc发布了新的文献求助150
11秒前
李爱国的应助被zww采纳,获得10
11秒前
打打的应助被zww采纳,获得10
11秒前
12秒前
12秒前
12秒前
郑启发布了新的文献求助10
13秒前
琴酒发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192519
求助须知:如何正确求助?哪些是违规求助? 9579028
关于积分的说明 21863207
捐赠科研通 7792025
什么是DOI,文献DOI怎么找? 3436955
关于科研通互助平台的介绍 2560622
邀请新用户注册赠送积分活动 2483832